BRPI0516872A - uso de compostos orgánicos - Google Patents

uso de compostos orgánicos

Info

Publication number
BRPI0516872A
BRPI0516872A BRPI0516872-4A BRPI0516872A BRPI0516872A BR PI0516872 A BRPI0516872 A BR PI0516872A BR PI0516872 A BRPI0516872 A BR PI0516872A BR PI0516872 A BRPI0516872 A BR PI0516872A
Authority
BR
Brazil
Prior art keywords
organic compounds
calcitonin
relates
patients
specifically
Prior art date
Application number
BRPI0516872-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Moise Azria
Claus Christiansen
Original Assignee
Nordic Bioscience As
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33443790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0516872(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nordic Bioscience As, Novartis Ag filed Critical Nordic Bioscience As
Publication of BRPI0516872A publication Critical patent/BRPI0516872A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0516872-4A 2004-10-12 2005-10-10 uso de compostos orgánicos BRPI0516872A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0422644.5A GB0422644D0 (en) 2004-10-12 2004-10-12 Organic compounds
PCT/EP2005/010892 WO2006040114A1 (en) 2004-10-12 2005-10-10 Use of organic compounds

Publications (1)

Publication Number Publication Date
BRPI0516872A true BRPI0516872A (pt) 2008-09-23

Family

ID=33443790

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516872-4A BRPI0516872A (pt) 2004-10-12 2005-10-10 uso de compostos orgánicos

Country Status (13)

Country Link
US (1) US20090048157A1 (OSRAM)
EP (1) EP1802328A1 (OSRAM)
JP (1) JP2008515947A (OSRAM)
KR (1) KR20070061864A (OSRAM)
CN (1) CN101035556A (OSRAM)
AU (1) AU2005293802A1 (OSRAM)
BR (1) BRPI0516872A (OSRAM)
CA (1) CA2580766A1 (OSRAM)
GB (1) GB0422644D0 (OSRAM)
MX (1) MX2007004259A (OSRAM)
RU (1) RU2007117492A (OSRAM)
TW (1) TW200628168A (OSRAM)
WO (1) WO2006040114A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101309674A (zh) 2005-11-17 2008-11-19 诺瓦提斯公司 药物组合物
CN102292346B (zh) 2009-01-22 2015-12-02 关键生物科学有限公司 肥胖的治疗
MX351092B (es) * 2011-11-02 2017-10-02 Keybioscience Ag Analogos peptidicos para tratar enfermedades y trastornos.
US9533022B2 (en) 2011-11-02 2017-01-03 KeyBioscience A/S Peptide analogs for treating diseases and disorders
EP3095484B1 (en) * 2011-11-02 2018-05-02 KeyBioscience AG Calcitonin mimetics for treating diseases and disorders
CN107345965A (zh) * 2016-05-04 2017-11-14 广州优迪生物科技有限公司 一种同时检测N-MID和β-CTX的双标记时间分辨荧光免疫分析方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
GB9108634D0 (en) * 1991-04-23 1991-06-12 Ciba Geigy Pharmaceutical compositions
DE726075T1 (de) * 1995-02-08 1996-12-12 Therapicon Srl Nicht-inorganische pharmazeutische salzige Lösungen zur endonasale Verabreichung
IT1282374B1 (it) * 1996-01-31 1998-03-20 Therapicon Srl Composizioni farmaceutiche parenterali a base di calcitonine sintetiche a ph controllato con basso indice di dolorosita'
NZ534409A (en) * 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US20040110170A1 (en) * 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
TW200411053A (en) * 2002-12-30 2004-07-01 Ind Tech Res Inst Nucleic acid encoding recombinant salmon calcitionin, expression vector thereof, and method for producing recombinant salmon calcitonin therewith

Also Published As

Publication number Publication date
WO2006040114A1 (en) 2006-04-20
JP2008515947A (ja) 2008-05-15
TW200628168A (en) 2006-08-16
CN101035556A (zh) 2007-09-12
GB0422644D0 (en) 2004-11-10
MX2007004259A (es) 2007-05-11
CA2580766A1 (en) 2006-04-20
RU2007117492A (ru) 2008-11-20
AU2005293802A1 (en) 2006-04-20
KR20070061864A (ko) 2007-06-14
EP1802328A1 (en) 2007-07-04
US20090048157A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
CR9312A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
BRPI0510043A (pt) método de tratamento de dor neuropática usando antagonista de receptor crth2
BRPI0615150A2 (pt) agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo
UY32030A (es) "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0814299B8 (pt) preparação sólida compreendendo alogliptina e cloridreto de metformina, uso de uma preparação sólida, e, métodos para estabilizar um composto em uma preparação sólida, e para produzir uma preparação sólida
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
PT1506781E (pt) Composicao para tratamento vaginal
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
BRPI0517701A8 (pt) métodos de tratamento de diabetes mellitus
BRPI0514721A (pt) uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
DE602004004817D1 (de) Myo-inositol hexaphosphat zur topischen verwendung
WO2008049990A3 (fr) Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
CR11368A (es) Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida
AR057643A1 (es) Lacosamida para terapia adjunta
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas
EA201690490A1 (ru) Миметики инсулиноподобного фактора роста для применения в терапии
TW200628168A (en) Use of organic compounds
CL2008002884A1 (es) Composicion farmaceutica compuesta por meloxicam o calecoxib y alopurinol; composicion farmaceutica; y uso para el control y tratamiento de la gota, la artritis gotosa y otras patologias relacionadas.
PA8800601A1 (es) Productos quimioterapeuticos cristalinos
PA8800401A1 (es) Productos quimioterapeuticos cristalinos
NO20053339L (no) Levalbuterolsalt.
CR11387A (es) Productos quimioterapeuticos cristalinos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.